/ /

  • linkedin
  • Increase Font
  • Sharebar

    Study explores ranibizumab as treatment for ROP


    Study rationale

    In a previous study investigating infants treated with bevacizumab for ROP, Dr. Kusaka and colleagues showed that bevacizumab was measureable in serum and that the serum VEGF level was reduced for at least 2 weeks. He also mentioned a study from Taiwanese investigators that found serum VEGF was suppressed for up to 8 weeks in infants treated with intravitreal bevacizumab for ROP.

    “It was shown that in adults with age-related macular degeneration, ranibizumab caused less suppression of plasma VEGF than aflibercept (Eylea, Regeneron) or bevacizumab,” Dr. Kusaka said. “So we were interested in whether in infants with ROP, intravitreal ranibizumab would cause less systemic VEGF suppression than bevacizumab.”

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results